Sangeeta N. Bhatia - Jun 2, 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Jun 2, 2021
Transactions value $
-$117,216
Form type
4
Date filed
6/4/2021, 04:03 PM
Next filing
Apr 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$59.6K -285 -4.96% $208.96 5.47K Jun 2, 2021 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$32.1K -153 -2.8% $210.01 5.31K Jun 2, 2021 Direct F1, F3, F4
transaction VRTX Common Stock Sale -$25.5K -121 -2.28% $211.00 5.19K Jun 2, 2021 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $208.96 (range $208.64 to $209.48).
F3 Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $210.01 (range $209.64 to $210.34).
F5 Open market sales reported on this line occurred at a weighted average price of $211.00 (range $210.70 to $211.50).